Coronary disease & ACS

Temporal changes in coronary plaque as assessed by an artificial intelligence–based optical coherence tomography: from the first-in-human trial on DREAMS 3G scaffold

Eur Heart J Cardiovasc ImagingPublished Secondary analysis of the BIOMAG-I first-in-human trial

Authors' conclusion

The larger the fibrous tissue in the lesion at baseline, the larger the luminal loss seen at 6 and 12 M. Following the implantation of DREAMS 3G, favourable healing of the vessel coronary wall occurs as shown by a decrease in the lipid area and an increase in fibrous tissue.

Study context

Population
Patients treated with the DREAMS 3G scaffold, imaged by optical coherence tomography (OCT) pre- and post-implantation and at 6 and 12 M
Participants
116 patients
Comparison
Baseline plaque composition vs luminal late loss; serial plaque changes baseline vs 6 and 12 M after DREAMS 3G
Primary endpoint
Impact of baseline plaque composition on DREAMS 3G luminal late loss; serial plaque changes (lipid, calcium, fibrous tissue)
Follow-up
6 and 12 M
Methodological detailsartificial intelligence–based OCT analysis, serial imaging
  • Artificial intelligence–based OCT analysis
  • Serial imaging

Primary result

As reported in the abstract

Larger minimum lumen area (MLA) differences at 12 M associated with significantly larger baseline fibrous tissue content
P = 0.0003
Reduction in lipid area vs pre-DREAMS 3G OCT at 6 M
24.8%
Reduction in lipid area vs pre-DREAMS 3G OCT at 12 M
20.9%
Lipid area reductions at 6 and 12 M, P
P < 0.001
Increase in fibrous tissue at 6 M
48.4%
Increase in fibrous tissue at 12 M
36.0%
Fibrous tissue increases at 6 and 12 M, P
P < 0.001

Original publication

Temporal changes in coronary plaque as assessed by an artificial intelligence–based optical coherence tomography: from the first-in-human trial on DREAMS 3G scaffold. Eur Heart J Cardiovasc Imaging. Published 4 November 2023. doi:10.1093/ehjci/jead299

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.